Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Sustained-Release Tablets 30 X 4 mg |
|
34289 | 8871 |
|
Sustained-Release Tablets 30 X 8 mg |
|
34294 | 8872 |
Related information
Dosage
The recommended starting dose is 4 mg once daily. Based upon individual response, the dose may be increased to 8 mg once daily. The maximum daily dose is 8 mg.
Indications
Treatment of symptoms that may occur in patients with overactive bladder syndrome such as increased urinary frequency and/or urgency and/or urgency incontinence.
Contra-Indications
* Hypersensitivity to the active substance or to peanut or soya or to any of the excipients.
* Urinary retention.
* Gastric retention.
* Uncontrolled narrow angle glaucoma.
* Myasthenia gravis.
* Severe hepatic impairment (Child Pugh C).
* Concomitant use of potent CYP3A4 inhibitors in subjects with moderate to severe hepatic or renal impairment.
* Severe ulcerative colitis.
* Toxic megacolon.
Special Precautions
Please refer to the license holder for further details.
Side Effects
Please refer to the license holder for further details.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details.
